Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706977 · ClinicalTrials.gov registry record · Phase 1
The Effect of Dopamine on Diabetic Retinopathy
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02706977 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 60 participants.
The verdict
NCT02706977, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of electroretinogram (ERG) using a novel handheld system, RETeval, and evaluate contrast sensitivity testing in detecting pre-clinical retinopathy on a tablet device. Investigators also seek to assess if a medication called Sinemet™ CR can improve the electrical functions of the eye in participants with diabetes mellitus. This study will include a total of 45 participants; 30 with diabetes mellitus and 15 age-matched non-diabetic controls. Participants with diabetes mellitus and electroretinogram (ERG) delays will be randomized to a low or high dose Sinemet CR group.
Interventions
- DRUG Low Dose Sinemet CR
- DRUG High Dose Sinemet CR
- DEVICE RETeval Electroretinogram (ERG) Testing
- OTHER Contrast Sensitivity Testing
- OTHER Visual Acuity Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02706977
The ClinicalTrials.gov registry entry for NCT02706977 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Low Dose Sinemet CR is the first listed.
NCT02706977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02706977 about?
NCT02706977 is a clinical study titled "The Effect of Dopamine on Diabetic Retinopathy". The purpose of this study is to evaluate the use of electroretinogram (ERG) using a novel handheld system, RETeval, and evaluate contrast sensitivity testing in detecting pre-clinical retinopathy on a tablet device. Investigators also seek to assess if a medication called Sinemet™ CR can improve th...
What is the current status of trial NCT02706977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-01. Estimated completion is 2019-08-15.
What interventions are being tested in trial NCT02706977?
The interventions under investigation include: Low Dose Sinemet CR (DRUG), High Dose Sinemet CR (DRUG), RETeval Electroretinogram (ERG) Testing (DEVICE), Contrast Sensitivity Testing (OTHER), Visual Acuity Testing (OTHER).
Who is sponsoring clinical trial NCT02706977?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.